Publications

• Commentary on Gregory et al.: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation.Springer SA. Addiction. 2025 Jan; 2024 Nov 4. PMID: 39494653.
• Plans to end HIV should address substance use.Springer SA. Lancet HIV. 2024 Dec. PMID: 39632048.
• Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, Günthard HF, Thompson MA, Bedimo RJ, Benson CA, Buchbinder SP, Crabtree-Ramirez BE, Del Rio C, Eaton EF, Eron JJ Jr, Hoy JF, Lehmann C, Molina JM, Jacobsen DM, Saag MS. JAMA. 2024 Dec 1; 2024 Dec 1. PMID: 39616604.
• Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails.Springer SA. JAMA Netw Open. 2024 Sep 3; 2024 Sep 3. PMID: 39316405.
• HIV and Substance Use Disorders.Lier AJ, Tarfa A, Shenoi SV, Kuo I, Springer SA. Infect Dis Clin North Am. 2024 Sep; 2024 Jul 2. PMID: 38960783.
• Perspectives on benefits and risks of creation of an "injection drug use" billing code.Sundaram G, Sato T, Goodman-Meza D, Haddad M, Thakarar K, Feinberg J, Springer SA, Barton K, Butler N, Eaton EF, Wurcel AG. J Subst Use Addict Treat. 2024 Sep; 2024 May 10. PMID: 38735482.
• Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases.Parchinski K, Neirinckx V, Frank C, Di Paola A, Tarfa A, Shenoi S, Vander Wyk B, Roth P, Ghantous T, Wegman MK, Strong M, Levin FR, Brady K, Nunes E, Litwin AH, Springer SA. Open Forum Infect Dis. 2024 Jul; 2024 Jul 10. PMID: 39022389.
• Serious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder.Springer SA. JAMA Netw Open. 2024 Jul 1; 2024 Jul 1. PMID: 39046746.
• Considerations when prescribing opioid agonist therapies for people living with HIV.Tarfa A, Lier AJ, Shenoi SV, Springer SA. Expert Rev Clin Pharmacol. 2024 Jul; 2024 Jul 4. PMID: 38946101.
• Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non-Clinicians.Di Paola A, Farabee D, Springer SA. Psychiatr Res Clin Pract. 2023 Fall; 2023 Aug 15. PMID: 37711754.
• Integrated Care Models: HIV and Substance Use.Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Curr HIV/AIDS Rep. 2023 Oct; 2023 Sep 12. PMID: 37698755.
• Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where They Are.Springer SA. J Gen Intern Med. 2023 Sep; 2023 Mar 31. PMID: 37002460.
• Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.Seval N, Nunez J, Roth P, Schade M, Strong M, Frank CA, Litwin AH, Levin FR, Brady KT, Nunes EV, Springer SA. J Addict Med. 2023 Jul-Aug 01; 2023 Jan 26. PMID: 37579095.
• Corrigendum to 'Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder' [J. Subst. Abuse Treat. vol. 142 (2022)/108852].Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. J Subst Use Addict Treat. 2023 Jul; 2023 Jun 3. PMID: 37271717.
• The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV.Parchinski K, Di Paola A, Wilson AP, Springer SA. Drug Alcohol Depend Rep. 2023 Jun; 2023 Apr 14. PMID: 37159815.
• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, Lehmann C, Springer SA, Sax PE, Thompson MA, Benson CA, Buchbinder SP, Del Rio C, Eron JJ Jr, Günthard HF, Molina JM, Jacobsen DM, Saag MS. JAMA. 2023 Jan 3. PMID: 36454551.
• The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study.Saunders EC, Satcher MF, Monico LB, McDonald RD, Springer SA, Farabee D, Gryczynski J, Nyaku A, Reeves D, Kunkel LE, Schultheis AM, Schwartz RP, Lee JD, Marsch LA, Waddell EN. Health Justice. 2022 Dec 19; 2022 Dec 19. PMID: 36529829.
• Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder.Lier AJ, Vander Wyk B, Di Paola A, Springer SA. Open Forum Infect Dis. 2022 Nov; 2022 Nov 14. PMID: 36467300.
• Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. J Subst Abuse Treat. 2022 Nov; 2022 Jul 30. PMID: 35988513.
• Gender differences among persons entering medication treatment for opioid use disorder in the community.Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Am J Addict. 2022 Sep; 2022 Jun 2. PMID: 35652902.
• Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons.Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. BMC Infect Dis. 2022 Apr 15; 2022 Apr 15. PMID: 35428213.
• Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Addict Sci Clin Pract. 2022 Mar 7; 2022 Mar 7. PMID: 35255967.
• Commentary on Murphy et al.: What will it take to prescribe extended-release naltrexone to treat alcohol use disorder?Springer SA. Addiction. 2022 Feb; 2021 Sep 22. PMID: 34549844.
• Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Addict Sci Clin Pract. 2022 Jan 31; 2022 Jan 31. PMID: 35101115.
• Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence.Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Contemp Clin Trials Commun. 2021 Dec; 2021 Nov 11. PMID: 34825103.
• Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South Africa.Grammatico MA, Moll AP, Choi K, Springer SA, Shenoi SV. J Int AIDS Soc. 2021 Nov. PMID: 34826363.
• Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions.Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, Springer SA. Int J Drug Policy. 2021 Oct; 2021 May 18. PMID: 34020864.
• A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes.McNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimshaw AA, Springer SA. Open Forum Infect Dis. 2021 Aug; 2021 Jun 2. PMID: 34430670.
• Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder.Seval N, Frank CA, Litwin AH, Roth P, Schade MA, Pavlicova M, Levin FR, Brady KT, Nunes EV, Springer SA. Contemp Clin Trials. 2021 Jun; 2021 Apr 7. PMID: 33838307.
• Hepatitis C in the United States: One Step Forward, Two Steps Back.Rio CD, Springer SA. Am J Public Health. 2021 May. PMID: 33826392.
• Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder.Biondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, Springer SA. Contemp Clin Trials Commun. 2021 Mar; 2021 Jan 6. PMID: 33490708.
• Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.Biondi BE, Frank CA, Forray A, Springer SA. Subst Abus. 2021; 2021 Mar 22. PMID: 33750285.
• A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.Cioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. J Subst Abuse Treat. 2020 Dec; 2020 Sep 22. PMID: 33138929.
• Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose.Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. AIDS. 2020 Nov 15. PMID: 32826391.
• Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing.Springer SA, Masciotra S, Johnson JA, Campbell S. Open Forum Infect Dis. 2020 Nov; 2020 Oct 10. PMID: 33204760.
• Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes!Springer SA, Del Rio C. Clin Infect Dis. 2020 Oct 23. PMID: 32011653.
• Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.Springer SA, Barocas JA, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, Del Rio C. J Infect Dis. 2020 Sep 2. PMID: 32877568.
• Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics.Springer SA, Del Rio C. Infect Dis Clin North Am. 2020 Sep. PMID: 32782107.
• Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic.Springer SA, Rio CD. Infect Dis Clin North Am. 2020 Sep. PMID: 32782106.
• The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review.Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. Infect Dis Clin North Am. 2020 Sep. PMID: 32782102.
• A Call to Action to Combat the Opioid Epidemic Among Women.Springer SA, Biondi BE, Frank C, El-Bassel N. J Addict Med. 2020 Sep/Oct. PMID: 32011410.
• Aortic Valve Surgery Outcomes Reporting and Implications for Persons Who Use Drugs With Infectious Endocarditis.Springer SA. Clin Infect Dis. 2020 Jul 27. PMID: 31588502.
• Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics: A Report From the National Academies of Sciences, Engineering, and Medicine.Springer SA, Merluzzi AP, Del Rio C. JAMA. 2020 Jul 7. PMID: 32159771.
• A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?Biondi BE, Zheng X, Frank CA, Petrakis I, Springer SA. Am J Addict. 2020 Jul; 2020 Apr 29. PMID: 32346932.
• Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder.Springer SA. Clin Infect Dis. 2020 Jun 10. PMID: 31346595.
• Pregnancy, Substance Use, and Research: How do We Protect Women While Increasing Their Participation in Research?Biondi BE, Frank C, Springer SA. J Addict Med. 2020 May/Jun. PMID: 31403523.
• Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases.Serota DP, Barocas JA, Springer SA. Clin Infect Dis. 2020 Feb 14. PMID: 31420651.
• Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases.Seval N, Eaton E, Springer SA. Open Forum Infect Dis. 2020 Jan; 2019 Dec 24. PMID: 31993454.
• Self-reported antiretroviral therapy adherence and viral load in criminal justice-involved populations.Cunningham WE, Nance RM, Golin CE, Flynn P, Knight K, Beckwith CG, Kuo I, Spaulding A, Taxman FS, Altice F, Delaney JA, Crane HM, Springer SA. BMC Infect Dis. 2019 Oct 29; 2019 Oct 29. PMID: 31664910.
• Reduced Sexual Risk Behaviors Among Persons With HIV After Release From the Criminal Justice System.Biondi BE, Frank C, Horn BP, Springer SA. Open Forum Infect Dis. 2019 Oct; 2019 Sep 21. PMID: 31660369.
• Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. J Subst Abuse Treat. 2019 Sep; 2019 May 10. PMID: 31370983.
• Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics.Springer SA, Korthuis PT, Del Rio C. Ann Intern Med. 2019 Apr 2. PMID: 30934074.
• Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.Fanucchi L, Springer SA, Korthuis PT. Curr HIV/AIDS Rep. 2019 Feb. PMID: 30684117.
• Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations.Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA. Drug Alcohol Depend. 2019 Jan 1; 2018 Oct 23. PMID: 30412898.
• Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop.Springer SA, Korthuis PT, Del Rio C. Ann Intern Med. 2018 Sep 4; 2018 Jul 13. PMID: 30007032.
• Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. J Acquir Immune Defic Syndr. 2018 Sep 1. PMID: 29781884.
• Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision.Mbaba M, Brown SE, Wooditch A, Kiss M, Murphy A, Kumari S, Taxman F, Altice F, Lawson WB, Springer SA. Subst Use Misuse. 2018 Jul 29; 2018 Jan 15. PMID: 29333954.
• Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative.Beckwith CG, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, Springer SA, Loeliger KB, Franks J, Christopoulos K, Lorvick J, Kahana SY, Young R, Seal DW, Zawitz C, Delaney JA, Crane HM, Biggs ML. PLoS One. 2018; 2018 May 22. PMID: 29787580.
• Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. J Acquir Immune Defic Syndr. 2018 May 1. PMID: 29373393.
• A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, Springer SA. J Subst Abuse Treat. 2018 Mar; 2018 Jan 5. PMID: 29415856.
• Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Drug Alcohol Depend. 2017 Oct 1; 2017 Aug 5. PMID: 28806638.
• Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium.Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. AIDS Behav. 2017 Oct. PMID: 28188460.
• Corrigendum to 'An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone' [Journal of Substance Abuse Treatment 47 (2014) 35-40].Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. J Subst Abuse Treat. 2017 Jun; 2017 Mar 18. PMID: 28476270.
• Corrigendum to "Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community" [Contemp. Clin. Trials (2014) 209-218].Springer SA, Altice FL, Herme M, Di Paola A. Contemp Clin Trials. 2017 Jun; 2017 Mar 21. PMID: 28341227.
• Cohort profile: seek, test, treat and retain United States criminal justice cohort.Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Subst Abuse Treat Prev Policy. 2017 May 16; 2017 May 16. PMID: 28511680.
• Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Drug Alcohol Depend. 2017 May 1; 2017 Mar 10. PMID: 28334661.
• An exploratory study of therapeutic misconception among incarcerated clinical trial participants.Christopher PP, Stein MD, Springer SA, Rich JD, Johnson JE, Lidz CW. AJOB Empir Bioeth. 2016; 2015 Jun 24. PMID: 26709382.
• HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study.Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. AIDS Care. 2016; 2015 Aug 14. PMID: 26275122.
• Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Springer SA, Brown SE, Di Paola A, Altice FL. Drug Alcohol Depend. 2015 Dec 1; 2015 Oct 28. PMID: 26560326.
• The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review : Alcohol and the HIV Continuum of Care.Vagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. Curr HIV/AIDS Rep. 2015 Dec. PMID: 26412084.
• Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions.Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. J Acquir Immune Defic Syndr. 2015 Jun 1. PMID: 25978482.
• Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study.Lincoln T, Simon-Levine D, Smith J, Donenberg GR, Springer SA, Zaller N, Altice FL, Moore K, Jordan AO, Draine J, Desabrais M. J Correct Health Care. 2015 Apr. PMID: 25788608.
• Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS).Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. J Correct Health Care. 2015 Jan. PMID: 25559628.
• HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.Meyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. Lancet HIV. 2014 Nov 1. PMID: 25473651.
• Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Contemp Clin Trials. 2014 Nov; 2014 Sep 18. PMID: 25240704.
• A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community.Di Paola A, Altice FL, Powell ML, Trestman RL, Springer SA. Health Justice. 2014 Oct 29. PMID: 25606368.
• An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. J Subst Abuse Treat. 2014 Jul; 2014 Mar 12. PMID: 24674234.
• Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. JAMA Intern Med. 2014 May. PMID: 24687044.
• Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.Springer SA, Altice FL, Herme M, Di Paola A. Contemp Clin Trials. 2014 Mar; 2013 Dec 31. PMID: 24384538.
• Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail.Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. AIDS Behav. 2013 Oct. PMID: 23673792.
• Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study.Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. AIDS Behav. 2013 Oct. PMID: 23142854.
• The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review.Springer SA, Dushaj A, Azar MM. AIDS Behav. 2012 Nov. PMID: 22644066.
• Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes.Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Contemp Clin Trials. 2012 Mar; 2011 Nov 12. PMID: 22101218.
• High rates of depressive symptomatology among injecting drug users in Saskatoon, Canada.Springer SA. Evid Based Ment Health. 2012 Feb; 2011 Nov 1. PMID: 22044870.
• Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. PLoS One. 2012; 2012 May 31. PMID: 22719814.
• Public health implications for adequate transitional care for HIV-infected prisoners: five essential components.Springer SA, Spaulding AC, Meyer JP, Altice FL. Clin Infect Dis. 2011 Sep. PMID: 21844030.
• Substance abuse, violence, and HIV in women: a literature review of the syndemic.Meyer JP, Springer SA, Altice FL. J Womens Health (Larchmt). 2011 Jul; 2011 Jun 13. PMID: 21668380.
• Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States.Chen NE, Meyer JP, Springer SA. Infect Dis Rep. 2011 Jan 1. PMID: 23745166.
• HIV Treatment in the Criminal Justice System: Critical Knowledge and Intervention Gaps.Meyer JP, Chen NE, Springer SA. AIDS Res Treat. 2011; 2011 Jul 12. PMID: 21776379.
• HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners.Springer SA, Azar MM, Altice FL. Am J Drug Alcohol Abuse. 2011 Jan; 2010 Dec 21. PMID: 21171933.
• A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization.Azar MM, Springer SA, Meyer JP, Altice FL. Drug Alcohol Depend. 2010 Dec 1; 2010 Aug 11. PMID: 20705402.
• Neurocognitive impairment and HIV risk factors: a reciprocal relationship.Anand P, Springer SA, Copenhaver MM, Altice FL. AIDS Behav. 2010 Dec. PMID: 20232242.
• Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.Springer SA, Chen S, Altice FL. J Urban Health. 2010 Jul. PMID: 20177974.
• Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners.Springer SA. Addiction. 2010 Feb. PMID: 20078481.
• Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy.Springer SA, Chen S, Altice F. AIDS Care. 2009 Aug. PMID: 20024753.
• Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial.Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. J Acquir Immune Defic Syndr. 2009 Feb 1. PMID: 19131891.
• A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.Springer SA, Bruce RD. J Opioid Manag. 2008 Mar-Apr. PMID: 18557164.
• Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy.Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. AIDS Behav. 2008 Mar; 2007 Dec 18. PMID: 18085432.
• Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial.Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. J Acquir Immune Defic Syndr. 2007 Dec 15. PMID: 18193497.
• Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Clin Infect Dis. 2007 Sep 15; 2007 Aug 13. PMID: 17712763.